tradingkey.logo

enVVeno Medical Corp

NVNO
10.420USD
+1.070+11.44%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
6.02MMarktkapitalisierung
VerlustKGV TTM

enVVeno Medical Corp

10.420
+1.070+11.44%

mehr Informationen über enVVeno Medical Corp Unternehmen

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp Informationen

BörsenkürzelNVNO
Name des UnternehmensenVVeno Medical Corp
IPO-datumMay 31, 2018
CEOBerman (Robert A)
Anzahl der mitarbeiter37
WertpapierartOrdinary Share
GeschäftsjahresendeMay 31
Addresse70 Doppler
StadtIRVINE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92618
Telefon19492612900
Websitehttps://envveno.com/
BörsenkürzelNVNO
IPO-datumMay 31, 2018
CEOBerman (Robert A)

Führungskräfte von enVVeno Medical Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.64K
-140.00%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+23.00%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Andere
71.72%
Aktionäre
Aktionäre
Anteil
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.92%
CM Management, LLC
5.45%
The Vanguard Group, Inc.
1.30%
Andere
71.72%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
9.48%
Investment Advisor
8.80%
Private Equity
7.67%
Hedge Fund
7.22%
Investment Advisor/Hedge Fund
1.68%
Research Firm
1.18%
Venture Capital
0.18%
Andere
63.79%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
80
169.95K
25.92%
-68.67K
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Satterfield (Thomas A Jr)
1.82M
9.02%
+1.82M
--
Nov 14, 2025
Perceptive Advisors LLC
1.76M
8.7%
+474.07K
+36.89%
Sep 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
6.72%
+500.00K
+58.19%
Sep 30, 2025
CM Management, LLC
600.00K
2.97%
+600.00K
--
Sep 30, 2025
The Vanguard Group, Inc.
861.19K
4.26%
+162.85K
+23.32%
Sep 30, 2025
Berman (Robert Andrew)
222.24K
1.1%
+200.00K
+899.44%
Oct 17, 2025
Geode Capital Management, L.L.C.
201.24K
1%
+1.74K
+0.87%
Sep 30, 2025
J.P. Morgan Securities LLC
182.32K
0.9%
+22.00
+0.01%
Sep 30, 2025
Susquehanna International Group, LLP
154.47K
0.76%
+154.47K
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI